
ESMO 2016: Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer
A phase III trial of sunitinib has met its primary endpoint of disease-free survival for…
A phase III trial of sunitinib has met its primary endpoint of disease-free survival for…